Methods of screening for antagonists of APM1/GZIP

Details Methods of screening for antagonists of APM1/GZIP Methods of screening for antagonists of APM1/GZIP

2008-07-22

2008-07-22

Landsman, Robert (Department: 1646)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

Reexamination Certificate

active

07402393

ABSTRACT:
The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. GZIP polypeptides have been identified that are believed to be beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing body mass and for treating metabolic-related diseases and disorders. These metabolic-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.

REFERENCES:
patent: WO 99/62939 (1999-12-01), None
patent: WO 01/51645 (2001-07-01), None
Kennedy, M. W. et al. “Hydrophobic Ligand Binding by Zn-α2-Glycoprotein, a Soluble Fat-Depleting Factor Related to Major Histocompatibility Complex Proteins”,Journal of Biological Chemistry, Sep. 14, 2001, pp. 35008-35013, vol. 276, No. 37.
GenBank Accession No. P25311, May 1, 1992, pp. 1-3, Ueyama, H. et al. “Zinc-Alpha-2-Glycoprotein Precursor”, XP-002239682.
Bürg, W. et al. “Preparation and Properties of Zn-α2-glycoprotein of Normal Human Plasma”,The Journal of Biological Chemistry, Apr. 1961, pp. 1066-1074, vol. 236, No. 4.
Araki, T. et al. “Complete Amino Acid Sequence of Human Plasma Zn-α2-glycoprotein and its Homology to Histocompatibility Antigens”,Proc. Natl. Acad. Sci. USA, Feb. 1988, pp. 679-683, vol. 85.
Freije, J. P. et al. “Human Zn-α2-glycoprotein cDNA Cloning and Expression Analysis in Benign and Malignant Breast Tissues”,FEBS, Sep. 1991, pp. 247-249, vol. 290, Nos. 1,2.
Ueyama, H. et al. “Cloning and Nucleotide Sequence of a Human Zn-α2-glycoprotein cDNA and Chromosomal Assignment of its Gene”,Biochemical and Biophysical Research Communications, Jun. 14, 1991, pp. 696-703, vol. 177, No. 2.
Sánchez, L. M. et al. “Biochemical Characterization and Crystalization of Human Zn-α2-glycoprotein, a Soluble Class I Major Histocompatibility Complex Homolog”,Proc. Natl. Acad. Sci. USA, Apr. 1997, pp. 4626-4630, vol. 94.
Todorov, P. T. et al. “Purification and Characterization of a Tumor Lipid-Mobilizing Factor”,Cancer Research, Jun. 1, 1998, pp. 2353-2358, vol. 58.
Hirai, K. et al. “Biological Evaluation of a Lipid-Mobilizing Factor Isolated from the Urine of Cancer Patients”,Cancer Research, Jun. 1, 1998, pp. 2359-2365, vol. 58.
Sánchez, L. M. et al. “Crystal Structure of Human ZAG, a Fat-Depleting Factor Related to MHC Molecules”,Science, Mar. 19, 1999, pp. 1914-1919, vol. 283.
Maenaka, K. et al. “MHC Superfamily Structure and the Immune System”,Current Opinion in Structural Biology, 1999, pp. 745-753, vol. 9.
Hale, L. P. et al. “Zinc α-2-Glycoprotein is Expressed by Malignant Prostatic Epithelium and May Serve as a Potential Serum Marker for Prostate Cancer”,Clinical Cancer Research, Apr. 2001, pp. 846-853, vol. 7.
Nakayashiki, N. et al. “Five New Alleles of Plasma Zn-Alpha 2-Glycoprotein Variants Phenotyped by Isoelectric Focusing and Immunoblotting in Twelve Populations”,Electrophoresis, Mar. 1992, pp. 154-157, vol. 13, No. 3.

Affiliated with

Also associated with

Rating

Methods of screening for antagonists of APM1/GZIP does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of screening for antagonists of APM1/GZIP, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of screening for antagonists of APM1/GZIP will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2807628